Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study

Maria Esposito1, Alessandro Giunta2, Paolo Gisondi3, Sara Tambone4, Marco Rovaris3, Valeria Manfreda2, Federico Pirro5, Cristina Pellegrini1, Maria Concetta Fargnoli1, Luca Bianchi2, Ketty Peris4,5, Giampiero Girolomoni3

1Dermatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
2Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
3Department of Medicine, Section of Dermatology and Venerology, University of Verona, Verona, Italy
4UOC di Dermatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
5Università Cattolica del Sacro Cuore, Rome, Italy

Correspondence
Maria Esposito, Dermatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, via Vetoio 67100 Coppito L’Aquila, Italy.
Email: espositomaria@virgilio.it, maria.esposito3@univaq.it

Funding information
Pfizer, Grant/Award Number: IIRWI216694

Abstract
In psoriasis patients, satisfaction and patients’ attitude toward treatment are heterogeneous depending on several factors and remain poorly investigated, although the availability of several new targeted therapeutic options. A multicentre cross-sectional investigation was conducted to estimate treatment satisfaction and attitudes (awareness, trust, and therapeutic alliance) in a large population of adult psoriasis patients undergoing a systemic biologic or non-biologic agent for moderate-to-severe plaque-type psoriasis. Patients’ satisfaction was measured using the Treatment Satisfaction Questionnaire for Medication II questionnaire and patients’ attitudes toward treatment were evaluated using a Lickert scale. Results were related to patients’ and treatment characteristics and therapeutic outcomes. The study included 899 psoriasis patients and demonstrated high-treatment satisfaction and positive attitudes toward systemic treatments, with greater influence of the perceived efficacy and the type of treatment. Biologic treatments and, in particular anti-IL17 agents showed higher results. More efforts in developing tools facilitating communication and exploring important aspects of patients’ view are needed.

KEYWORDS
biologics, patients’ attitudes, psoriasis, treatment satisfaction

1 INTRODUCTION

Several targeted biological treatments have become available in recent years for the treatment of patients with moderate-to-severe psoriasis. The effectiveness of these agents has been measured extensively with objective outcome measures, particularly the psoriasis area and severity index, and the physician global assessment, as well as measuring how the treatment impacts on patients’ quality of life. However, treatment satisfaction with medications and patients’ attitude toward treatment, including awareness, trust and therapeutic alliance have been poorly investigated for anti-psoriatic treatments. Recent studies demonstrated that patients’ satisfaction and preferences are heterogeneous and depend on several factors, including patient and disease characteristics, and type of treatment. However, when considering all therapeutic options, including topical agents, phototherapy, traditional systemic and biologic drugs, patient’s satisfaction remains low, leading to concerns about long term adherence and treatment persistence. When treating patients with psoriasis, patients’ perspective, satisfaction and positive attitude toward treatment should be addressed, as they are positively related to...
effectiveness, adherence to/persistence of treatment, and health-related quality of life.\textsuperscript{10-12} Despite the importance, generic treatment satisfaction questionnaires seem insufficient to adequately evaluate treatment satisfaction in psoriasis patients.\textsuperscript{13} In particular, the Treatment Satisfaction Questionnaire for Medication (TSQM) has been developed to gage satisfaction with medication for different indications,\textsuperscript{14,15} while attitudes are generally measured with a psychometric scale, the Lickert scale, a bipolar psychometric scaling method developed by Likert in 1932.\textsuperscript{16}

In the context of the current availability of many treatment options for psoriasis, the objective of this cross-sectional study was to investigate satisfaction and attitudes of patients toward systemic treatments. The results may provide indications to additional treatment benefit.

## 2 | PATIENTS AND METHODS

A multicentre cross-sectional explorative investigation was conducted to estimate unmet needs of current systemic anti-psoriatic agents by analyzing treatment satisfaction and attitudes in a large population of adult psoriasis patients undergoing a systemic biologic and non-biologic agent for moderate-to-severe plaque-type psoriasis. Patients' satisfaction score toward treatment was measured using the TSQM II questionnaire and patients' attitude toward treatment was evaluated using an attitude scale.\textsuperscript{14-17} Influence of patients' characteristics (sex, age, and educational level), treatment characteristics (drug, administration, frequency, and duration) and treatment outcomes (self-assessed efficacy, self-reported safety perception) on TSQM II scores and attitudes score were also analyzed.

Patients were recruited at three academic centres (University “Cattolica del Sacro Cuore” of Rome, University of Rome “Tor Vergata” and University of Verona) during the period October 2018 to June 2019. All the included subjects were consecutive patients undergoing a systemic treatment for at least 12 weeks with a biologic (adalimumab, certolizumab, etanercept, golimumab, infliximab, ixekizumab, secukinumab, ustekinumab) or a conventional non-biologic treatment (acitretin, ciclosporin, methotrexate and PUVA therapy), following the current recommendations from National guidelines, good clinical practice and Italian prescription criteria for systemic non-biologic and biologic agents.\textsuperscript{18}

Moreover, patients were able to understand and sign an informed consent and a declaration allowing the use of clinical records for scientific purposes, able to understand and complete the TSQM II questionnaire and the attitude questionnaire.\textsuperscript{14-17} Patients meeting any of the following criteria were excluded from participation: (i) pediatric patients, (ii) patients with a concurrent diagnosis of other immunological disorders, (iii) Participation in a clinical trial, and (iv) mentally unable.

Recorded data from subjects included: demographic information (age, sex), education level, treatment characteristics (drug, administration route, and frequency), treatment duration.

A subjective patient evaluation with a visual (11 point) scale was used to register patient perception of improvement from baseline to reach a completely patient-centered consistency of assessment. Subjective evaluation of clinical improvement (self-reported assessment) expressed by a visual analogic scale from 0 to 10 on disease severity before treatment initiation and at study entrance (Δ-Self reported assessment was calculated by the differential value from self-reported disease severity at baseline and at study entrance) and self-reported occurrence of side effects were registered. The TSQM II covers four domains of satisfaction with medications: efficacy, convenience, general satisfaction, and side effects. The scores for each domain range from 0 (extremely dissatisfied) to 100 (extremely satisfied) adding to a total score of 0 to 400. The questionnaire refers to 2 to 3 weeks prior to completion of the questionnaire. The Italian version of TSQM II validated by Quintiles has been used for this study.\textsuperscript{17}

The attitude questionnaire based on a psychometric Lickert scale explored three domains (trust, awareness, therapeutic alliance): two items regarding trust in medication and physician (score 0-10), eight items investigating awareness (score 0-40), and two items exploring therapeutic alliance (0-10) (Table 1). For each question, the positive attitude level was rated on a Lickert scale scoring from 0 (complete disagreement) to 5 (complete agreement).\textsuperscript{14} For each question/sentence, patients were invited to answer as best represents personal view toward the statement presented in the question or sentence.

A group of experts used a consensus panel process to generate the items (six dermatologist and one psychologist). A collection of commonly discussed questions, concerns and beliefs from patients in routine practice was performed and categorized as items expressing concept of trust, awareness and alliance; expert agreed that the questionnaire content was valid and experience-based on the basis of a personal (min > 15 years’ experience) in psoriasis treatment.

Patients’ interviews were performed by a trained psychologist to a number of 30 consecutive psoriasis patients referring to the out-patient clinics, in order to perform identification of ambiguous items, questions were corrected and minor changes in wording were made based on their comments to obtain a simple patient-oriented instrument.

Sensible data, including name or any identifying records, of patients accepting to participate to the study were anonymized. Ethical approval was obtained from the ethical committee of the University Hospital of Verona (protocol number: 1358CESC).

## 3 | STATISTICAL METHODS

Each variable was analyzed using descriptive statistics (number and percentage for categorical variables and mean ± SD or median with range for continuous variables, when appropriate). The TSQM II score and the attitude values were evaluated according to patients’ characteristics (sex, age, and educational level), treatment regimen (type, administration route, frequency, and duration) and treatment outcomes (self-assessed efficacy, self-reported safety perception). Moreover, treatment satisfaction and attitudes were also compared among patients who were treated with biologic agents according to the pharmacological class (anti-TNF alpha, anti-IL17, and anti IL12/23) and between each drug. Statistical differences between variables were calculated using the Fisher or the Chi-square test for categorical
variables or the Student's t-test, the Mann-Whitney test or Kruskal-Wallis test for continuous variables, as appropriate; correlations were performed with Spearman test. All the variables statistically significant in the univariate model were included in the multivariate analysis, performed by stepwise logistic regression. The confidence intervals (CI) were calculated with coverage of 95%. The results were considered statistically significant at $P < .05$. Statistics were performed by IBM-SPSS Statistics v. 25 software (Chicago, Illinois).

4 | RESULTS

4.1 | Study population

The study included 899 patients, 537 males (59.7%) and 362 females, with a mean age of 53.8 years (SD 14.8 years). Educational level was high school/university degree in 454 (50.5%), whereas the information was missing in 301 patients (33.5%). At the time of the study, 606 (67.4%) patients were under treatment with biologic and 293 (32.6%) were on non-biologic treatment; mean treatment duration was 26.9 weeks (±27.6 SD). Subcutaneous (s.c.) administration was the most frequent treatment modality reported by 735 (81.8%) patients, followed by oral administration in 121 (13.5%) and intravenous (i.v.) administration in 43 (4.8%). Self-reported assessment of disease severity before treatment initiation was 6.92 (±2.2 SD) while at study entrance was 0.79 (±1.5 SD).

Results of the total TSQM score was 334.2 (±62.8), with effectiveness mean score of 76.8 (±23.4), side effects mean score of 97.3 (±11.7), convenience mean value of 81.1 (±18.5), and global satisfaction mean value of 79.0 (±22.1). The attitude questionnaire showed high scoring, in particular the trust mean value was 8.3 (±1.7), the awareness mean value was 33.5 (±4.7) and the therapeutic alliance mean value was 8.9 (±1.3). Patients characteristics, drug usage and results of TSQM and attitude questionnaires are summarized in Table 2.
| Characteristics                     | Patients N = 899 (%) |
|-----------------------------------|---------------------|
| **Sex**                           |                     |
| M                                 | 537 (59.7)          |
| F                                 | 362 (40.3)          |
| **Age (years)**                   |                     |
| Mean ± (±SD)                      | 53.8 (±14.8)        |
| Median (range)                    | 54                  |
| **Educational level**             |                     |
| Primary/secondary                 | 144 (16.0)          |
| College/university                | 454 (50.5)          |
| Missing                           | 301 (33.5)          |
| **Drug**                          |                     |
| Methotrexate                      | 196 (21.8)          |
| Ciclosporin                       | 84 (9.3)            |
| Acitretin                         | 27 (3.0)            |
| PUVA therapy                      | 0 (0)               |
| Adalimumab                        | 128 (14.2)          |
| Certolizumab                      | 25 (2.8)            |
| Etanercept                        | 152 (16.9)          |
| Ixekizumab                        | 63 (7.0)            |
| Infliximab                        | 43 (4.8)            |
| Golimumab                         | 7 (0.8)             |
| Secukinumab                       | 113 (12.6)          |
| Ustekinumab                       | 75 (8.3)            |
| Biologic                          | 606 (67.4)          |
| Non-biologic                      | 293 (32.6)          |
| **Treatment duration (months)**   |                     |
| Mean (±SD)                        | 26.9 (±27.6)        |
| Median (range)                    | 18 (0-156)          |
| **Administration route**          |                     |
| Subcutaneous                      | 735 (81.8)          |
| Oral                              | 121 (13.5)          |
| i.v Intravenous                   | 43 (4.8)            |
| **Self-reported assessment of severity before treatment initiation** | | |
| Mean (±SD)                        | 6.92 (2.2)          |
| Median (range)                    | 7 (0-24)            |
| **Self-reported assessment of severity at study entrance** | | |
| Mean (±SD)                        | 0.79 (0.15)         |
| Median (range)                    | 0 (0-0.10)          |
| Δ-Self-reported-assessment        |                     |
| Mean (±SD)                        | 6.13 (2.5)          |
| Median (range)                    | 6 (−5 to 24)        |
| **Adverse events**                |                     |
| Mean (±SD)                        | 0.093 (±0.49)       |
| 0                                 | 844 (93.9)          |
| 1                                 | 47 (5.2)            |
| 4                                 | 3 (0.3)             |
| 5                                 | 5 (0.6)             |
| **Adverse events time of occurrence** |                  |
| Mean (±SD)                        | 5.27 (±1.9)         |
| **Attitude questionnaire**        |                     |
| Trust (mean value ±SD)            | 8.3 (±1.7)          |
| Awareness (mean value ±SD)        | 33.5 (±4.7)         |
| Alliance (mean value ±SD)         | 8.9 (±1.3)          |
| **TSQM II**                       |                     |
| Effectiveness (mean ± SD)         | 76.8 (±23.4)        |
| Side effects (mean ± SD)          | 97.3 (±11.7)        |
| Convenience (mean ± SD)           | 81.1 (±18.5)        |
| Global satisfaction (mean ± SD)   | 79.0 (±22.1)        |
| Sum (mean ± SD)                   | 334.2 (±62.8)       |
4.2 | Effects of sociodemographic features, treatment characteristics, and self-reported treatment outcomes

4.2.1 | Sociodemographic features

Results showed that TSQM value was significantly higher in men as compared with women (P = .002) and in patients with a higher educational level (P < .001) but inversely related with age (rho Spearman = −0.086; P = .010). In terms of trust, patients’ answers to items showed significantly higher values in men as compared with women (P = .025), absence of significance for age (rho Spearman = −0.062; P = .062), and higher values in patients with higher educational level (P = .006).

Patients’ answers exploring awareness showed significantly higher values in men as compared with women (P < .0001), absence of significance for age (rho Spearman = −0.026; P = .436), and higher values in patients with a higher educational level (P = .001). Besides, alliance was not related to sex (P = .575) and educational level (P = .170) and was inversely correlated with age (rho Spearman = −0.069; P = .038).

4.2.2 | Treatment characteristics

TSQM was significantly higher in patients treated with biologic as compared with non-biologic (P < .0001) and higher for i.v. than for s.c. and oral administration, as demonstrated by median TSQM values (Table 3) (P < .0001). TSQM was inversely related with administration frequency (rho Spearman = −0.235; P < .0001), with higher frequencies associated with lower satisfaction and directly related with treatment duration (rho spearman = 0.220; P < .0001).

In terms of trust, patients showed higher values when treated with biologics as compared with non-biologics (P < .0001), and for i.v. administration than s.c. and oral administration (median trust i.v. = 10.0, s.c. = 9.0; oral = 9.0) (P < .0001). Trust was inversely related with administration frequency (rho Spearman = −0.195; P < .0001) with more frequent drug administration associated with lower trust and directly related with treatment duration (rho spearman = 0.194; P < .0001). Awareness was significantly higher in patients treated with biologics as compared with non-biologics (P < .0001) and higher for i.v. administration than s.c. and oral administration (Table 3) (P < .0001). Awareness was inversely related with administration frequency (rho Spearman = −0.147; P < .0001) and directly related with treatment duration (rho spearman = 0.196; P < .0001). Moreover, alliance was significantly higher in patients treated with biologics as compared with non-biologics (P < .0001) and higher for i.v. and s.c. administration, and lower for oral administration (Table 3) (P < .0001). Alliance was inversely related with administration frequency (rho Spearman = −0.205; P < .0001) and directly associated with treatment duration (rho Spearman = 0.170; P < .0001).

4.2.3 | Self-reported treatment outcomes

TSQM was directly related with self-assessed efficacy (rho Spearman = 0.430, P < .0001), with higher values associated with elevated Δ Self-reported assessment values and inversely associated with occurrence of adverse events (median TSQM in patients without and with adverse events was 350.0 (100.0-425.0) vs 250.0 (27.8-400.0), respectively) (P < .0001). Trust was related with self-assessed efficacy with higher values associated with elevated Δ Self-reported assessment values (rho Spearman = 0.333, P < .0001) and inversely associated with occurrence of adverse events (median trust values in patients without and with adverse events was 9.0 and 8.0, respectively) (P < .006). Awareness was related with self-assessed efficacy with higher values associated with elevated Δ Self-reported assessment values (rho spearman = 0.296) (P < .0001) and inversely associated with adverse events occurrence (median awareness values in patients without and with adverse events was 33.0 (21.0-40.0) and 32.0 (21.0-40.0), respectively) (P < .028). Similarly, alliance was related with self-assessed efficacy (rho Spearman = 0.296, P < .0001) and inversely associated with occurrence of adverse events (median alliance values in patients without and with adverse events was 10.0 (0-10.0) and 8.0 (4.0-10.0), respectively) (P < .0001).

Differences in median values of TSQM, trust, awareness and alliance according to sociodemographic features, treatment characteristics, and self-reported treatment outcomes are indicated in Table 3.

4.2.4 | Multivariate analysis

TSQM

Results showed that the association between TSQM and sex (beta = 0.087, P = .003) and type of drug (biologic vs non-biologic) (beta = 0.138; P < .0001), self-assessed efficacy (Δ Self-reported assessment) (beta = 0.348, P < .0001), occurrence of adverse events (beta = −0.217 P < .0001) remained statistically significant.

Trust

Results showed that trust was dependent on sex (beta = 0.083; P = .008), biologic treatment (beta = 0.137, P = .001), and particularly on self-assessed efficacy (Δ Self-reported assessment) (beta = 0.301, P < .0001).

Awareness

Results showed that awareness was associated with sex (beta = 0.129; P < .0001), biologic treatment (beta = 0.089, P = .036) and self-assessed efficacy (Δ Self-reported assessment) (beta = 0.255, P < .0001).

Alliance

Results showed that alliance was dependent on self-assessed efficacy (Δ Self-reported assessment) (beta = 0.241, P < .0001) and occurrence of adverse events (beta = −0.120; P < .0001).
| Variables                      | TSQM          | Likert scale |                |                |                |                |                |
|-------------------------------|---------------|--------------|----------------|----------------|----------------|----------------|----------------|
|                               | Median value  | P            | Median value   | P              | Median value   | P              | Median value   | P              |
| Sex                           |               |              |                |                |                |                |                |
| M                             | 350.0 (100.0-425.0) | P = .002     | 9.0 (3.0-10.0) | P = .025       | 34.0 (22.0-40.0) | P < .0001     | 10.0 (0-10.0) | P = .575       |
| F                             | 330.6 (27.8-400.0) |             | 8.0 (3.0-10.0) |                | 32.0 (21.0-40.0) |                | 9.0 (40-10.0)  |                |
| Educational level*            |               |              |                |                |                |                |                |
| Low                           | 311.1 (211.1-400.0) | P < .001     | 8.0 (3.0-10.0) | P = .006       | 31.0 (21.0-40.0) | P = .001       | 9.0 (60-10.0)  | P = .122       |
| High                          | 327.8 (100.0-400.0) |             | 9.0 (3.0-10.0) |                | 32.0 (22.0-40.0) |                | 9.0 (40-10.0)  |                |
| Treatment                     |               |              |                |                |                |                |                |
| Non-biologic                 | 313.9 (27.8-425.0) | P < .0001    | 8.0 (3.0-10.0) | P < .0001      | 32.0 (21.0-40.0) | P < .0001     | 9.0 (60-10.0)  | P < .0001      |
| Biologic                      | 361.1 (100.0-400.0) |            | 9.0 (3.0-10.0) |                | 34.0 (22.0-40.0) |                | 10.0 (0-10.0)  |                |
| Drug route of administration  |               |              |                |                |                |                |                |
| Sc                            | 350.0 (100.0-425.0) | P < .0001    | 9.0 (3.0-10.0) | P < .0001      | 33.0 (22.0-40.0) | P < .0001     | 10.0 (60-10.0) | P < .0001      |
| Oral                          | 313.9 (27.8-400.0) |            | 8.0 (3.0-10.0) |                | 32.0 (21.0-40.0) |                | 8.0 (40-10.0)  |                |
| Iv                            | 366.7 (130.6-400.0) |            | 10.0 (4.0-10.0) |                | 34.0 (25.0-40.0) |                | 10.0 (0-10.0)  |                |
| Adverse events                |               |              |                |                |                |                |                |
| No                            | 350.0 (100.0-425.0) | P < .0001    | 9.0 (3.0-10.0) | P < .006       | 33.0 (21.0-40.0) | P = .028       | 10.0 (0-10.0)  | P < .0001      |
| Yes                           | 250.0 (27.8-400.0) |             | 8.0 (3.0-10.0) |                | 32.0 (21.0-40.0) |                | 8.0 (40-10.0)  |                |

Abbreviations: Iv, intravenous; Sc, subcutaneous; TSQM, Treatment Satisfaction Questionnaire for Medication.

*Educational level. Low: primary/secondary level, High: college/university level.
Comparison among biologic agents

Comparison of questionnaire results among patients treated with biologic agents according to the pharmacologic class (anti-TNF alpha, anti-IL17, and anti IL12/23) showed homogeneous results. TSQM values were significantly higher in patients treated with anti-IL17 compared to other treatments ($P < .0001$). Trust, awareness and alliance were significantly higher in patients treated with anti-IL17 compared to other treatments ($P < .0001$). (Figure 1).

In details, when we compared drugs in terms of median scores of TSQM, attitudes, also including a parallel evaluation of self-reported treatment outcomes ($\Delta$-Self reported assessment) in patients treated/not treated with each agent, we observed significantly better results for ixekizumab and secukinumab treated patients for all studied outcomes (Table 4), followed by infliximab showing significant results for TSQM, alliance and $\Delta$-Self reported assessment and ustekinumab showing significant values for trust and $\Delta$-Self reported assessment. Treatment with subcutaneous anti TNFs showed worse results, with etanercept demonstrating significant differences only in terms of TSQM and trust, adalimumab only in term of $\Delta$-Self reported assessment and CZP not demonstrating significant differences for any outcome. (Table 4).

**FIGURE 1** Comparison among biologic agents in term of satisfaction and attitudes (trust, awareness, and alliance)

5 | DISCUSSION

This study demonstrated high-treatment satisfaction and positive attitude of patients toward systemic treatments with greater influence of the perceived efficacy and the type of treatment. Biologic treatments and, in particular anti-IL17 agents, ixekizumab and secukinumab, showed better results in terms of satisfaction and positive attitudes, followed by infliximab, etanercept and ustekinumab while other subcutaneous anti TNF agents (adalimumab and certolizumab pegol) did not demonstrate significant results. As for perceived improvement from baseline, expressed by $\Delta$-Self reported assessment, better results were reached by patients undergoing ixekizumab, secukinumab and ustekinumab with ixekizumab showing largest median difference, followed by adalimumab, certolizumab and etanercept.

Many studies have been published about efficacy and safety of systemic agents for psoriasis, but information regarding treatment preferences, patients’ satisfaction and attitudes are scarce. Objective physician evaluation performed through validated severity scales may be discordant from patient-reported outcomes in psoriasis treatment, since these latter may be influenced by other factors referring to satisfaction and patient attitudes.19
### TABLE 4
Analysis of single agent median values of TSQM, attitudes and self-reported treatment outcomes (Δ-Self reported assessment). Bold number indicate statistically significant results p value <0.05

| Number of patients (%) | TSQM | Trust | Awareness | Alliance | Δ-Self reported assessment |
|------------------------|------|-------|-----------|----------|----------------------------|
| **Adalimumab** 128 (14.2) | No 3417 | **P = .399** | 9.0 | **P = .574** | 33.0 | **P < .584** | 9.0 | **P = .563** | 6.0 | **P = .028** |
| | Yes 350.0 | | 9.0 | | 34.0 | | 9.0 | | 6.0 | |
| **Certolizumab** 25 (2.8) | No 341.7 | **P = .788** | 9.0 | **P = .812** | 33.0 | **P = .824** | 9.0 | **P = .801** | 6.0 | **P = .339** |
| | Yes 334.1 | | 8.0 | | 32.0 | | 10.0 | | 6.0 | |
| **Etanercept** 152 (16.9) | No 333.3 | **P = .001** | 8.0 | **P = .039** | 33.0 | **P = .133** | 9.0 | **P = .811** | 6.0 | **P = .009** |
| | Yes 365.3 | | 9.0 | | 33.0 | | 10.0 | | 6.0 | |
| **Ixekizumab** 63 (70) | No 340.3 | **P < .001** | 9.0 | **P = .008** | 33.0 | **P = .001** | 9.0 | **P < .001** | 6.0 | **P < .001** |
| | Yes 400.0 | | 10.0 | | 36.0 | | 10.0 | | 8.0 | |
| **Infliximab** 43 (4.8) | No 341.7 | **P = .037** | 9.0 | **P = .170** | 33.0 | **P = .259** | 9.0 | **P < .001** | 6.0 | **P = .007** |
| | Yes 366.7 | | 10.0 | | 34.0 | | 10.0 | | 7.0 | |
| **Secukinumab** 113 (12.6) | No 336.1 | **P < .001** | 8.0 | **P = .001** | 33.0 | **P = .002** | 9.0 | **P < .001** | 6.0 | **P < .001** |
| | Yes 383.3 | | 9.0 | | 36.0 | | 10.0 | | 7.0 | |
| **Ustekinumab** 75 (8.3) | No 341.7 | **P = .721** | 8.0 | **P = .015** | 33.0 | **P = .318** | 10.0 | **P = .422** | 6.0 | **P < .001** |
| | Yes 347.2 | | 9.0 | | 32.0 | | 9.0 | | 7.0 | |

Abbreviation: TSQM, Treatment Satisfaction Questionnaire for Medication.
Patient satisfaction is a very important issue and has been often highly correlated with treatment adherence, drug survival, and treatment success.\(^{3,10-12}\) From a patient perspective, treatment efficacy and safety were reported to be the most important factors influencing treatment satisfaction, followed by doctor-patient communication and therapeutic alliance.\(^{20}\)

Studies showing suboptimal adherence rates in patients with psoriasis highlighted the need to improve patient compliance and treatment satisfaction,\(^ {20}\) taking into account patients' preference in the treatment decision-making process.\(^ {21}\)

The findings of our study demonstrated a high-treatment satisfaction and a positive attitude, in particular for trust and alliance domains followed by awareness, with a higher score for patients undergoing biologic treatments compared to non-biologic treatments. Among biologics, higher values were reported by patients treated with the newer anti-IL17 agents compared to anti-TNF alpha and anti-IL12/23 agents. Males demonstrated higher satisfaction, trust, and awareness whereas alliance did not show association with sex. Age showed inverse association with satisfaction and alliance and was not associated with trust and awareness. A higher educational level was associated with higher satisfaction and attitudes scores, except for alliance. Ongoing biologic treatment and i.v. administration was associated with higher satisfaction and positive attitude scores, while an inverse association with administration frequency was observed. Treatment duration and self-assessed efficacy demonstrated an association with all satisfaction and attitudes scores as well as drug-related adverse events occurrence.

Our results are in line with previous studies consistently showing that patients treated with biologic agents demonstrate higher treatment satisfaction.\(^ {8}\) However, patients' satisfaction toward all treatment modalities, including topical agents and phototherapy, remains modest. A possible explanation is that many patients might have not received treatment options commensurate with the severity/extent of their disease as recommended, leading to frustration and perceived insufficient efficacy, increasing need for information and search for available treatment options.\(^ {4}\)

Dermatologists need to communicate to psoriasis patients the feeling of “understanding the disease;” hope about its curability and disease control. These elements should be taken into account whenever educational interventions are planned.\(^ {22}\)

A recent review exploring treatment preference and satisfaction described a large heterogeneity and variability over time among psoriasis patients. The most important treatment attributes were the place (hospital/home) where the treatment was administered, probability of benefit, route of administration, and risk of adverse events.\(^ {5}\) Our results demonstrated a large impact on each satisfaction and attitudes domain of treatment-related characteristics including biologic agents, lower frequency of administration, longer treatment duration, i.v. administration, showing patient preference for inpatient or daily hospital management. A Canadian survey on 343 patients showed a greater treatment satisfaction among biologic users compared with non-biologic users. They also demonstrated that patients had poor information about treatment modalities and physicians may consider counseling these patients psoriasis management.\(^ {9}\)

Treatment satisfaction and positive attitudes including trust, awareness, and alliance are very important issues in psoriasis management. Understanding the disease and treatment experience of patients and their opinions using validated satisfaction tools and psychometric attitudes scales is crucial to improve doctor-patient relationship and the active role of patients in treatment decision making. Physician-patient relationship relies heavily on the patients' satisfaction with therapy and efforts have been made to find ideal instruments to be routinely used in clinical practice.\(^ {13}\) In 2017 the International Dermatology Outcome Measures (IDEOM) annual meeting established the limitation of current validated instruments and the need to develop, validate, and standardize a dermatology-specific treatment satisfaction measure.\(^ {13}\)

Limitations of this study include the exclusively subjective patient evaluation of treatment outcome and improvement from baseline due to the cross-sectional study nature, lacking an objective clinical disease measure and the use a non-validated attitude scale arising from a consensus panel of experts. However, positive characteristics of this study were the large sample size, multicenter nature, the completely patient-centered consistency of assessment and the use of the TSQM validated scale complemented by a psychometric attitude scale, which, although non-validated, helped communication and measurement of patients' feelings and opinion.

In conclusion, our findings describe the characteristics of patients' satisfaction and attitudes, exploring a difficult area of psoriasis management. Newer and valid tools facilitating communication and exploring important aspects of patients' view on treatments, their experience and relationship with clinicians are needed.

**CONFLICT OF INTEREST**

Maria Esposito has served as speaker and/or consultant for Abbvie, Almirall, Biogen, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Sanofi Genzyme, UCB. Alessandro Giunta has served has speaker and/or consultant for Abbvie, Biogen, Eli Lilly, Pfizer, UCB. Paolo Gisondi has been a consultant and/or speaker for Abbvie, Almirall, Celgene, Janssen, Leo-pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, UCB. Maria Concetta Fargnoli has served on advisory boards, received honoraria for lectures and research grants from Almirall, Abbvie, Galderma, Leo Pharma, Mylan, Medac Pharma, Celgene, Pierre Fabre, UCB, Eli Lilly, Pfizer, Janssen, Novartis, Sanofi-Genzyme, Roche, Sunpharma, and MSD. Luca Bianchi has served as consultant and speaker for Abbvie, Janssen, Pfizer and Novartis. Ketty Peris reports grants and personal fees from Almirall and AbbVie, and personal fees from Biogen, Lilly, Celgene, Galderma, Leo Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz, Sun Pharma and Janssen, outside the submitted work. Giampiero Girolomoni has been principal investigator in clinical trials sponsored by and/or and has received personal fees from AbbVie, Abiogen, Almirall, Alphasights, Amgen, Biogen, Bristol-Meyers Squibb, Celgene, Celltrion, Eli-Lilly, Genzyme, Gerson Lehrman Group, Guidepoint Global, Leo Pharma, Menlo
therapeutics, Novartis, OM Pharma, Pfizer, Regeneron, Samsung, Sandoz and UCB.

**AUTHOR CONTRIBUTION**

Study concept and design: Maria Esposito. Alessandro Giunta, Luca Bianchi, Ketty Peris, Giampiero Girolomoni. Acquisition, analysis, and interpretation of data: all authors. Drafting of manuscript: Maria Esposito, Alessandro Giunta, Maria Concetta Fargnoli, Luca Bianchi, Ketty Peris, Giampiero Girolomoni. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: Cristina Pellegrini. Obtained funding: Giampiero Girolomoni. Administrative, technical or material support: not applicable. Study supervision: Maria Esposito.

**DATA AVAILABILITY STATEMENT**

Data available on request from the authors

**ORCID**

Maria Esposito https://orcid.org/0000-0002-4773-6993
Paolo Gisondi https://orcid.org/0000-0002-1777-9001
Valeria Manfreda https://orcid.org/0000-0003-2099-5175

**REFERENCES**

1. Gisondi P, Geat D, Pizzolato M, Girolomoni G. State of the art and pharmaco-logical pipeline of biologics for chronic plaque psoriasis. Curr Opin Pharmacol. 2019;46:90-99.
2. Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156:258-269. https://doi.org/10.1001/jamadermatol.2019.4029.
3. Florek AG, Wang CJ, Armstrong AW. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Arch Dermatol Res. 2018;310(4):271-319.
4. Poulin Y, Papp KA, Wasel NR, et al. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. Int J Dermatol. 2010;49(12):1368-1375.
5. Umur N, Yamamoto S, Loerbroks A, Terris D. Elicitation and use of patients’ preferences in the treatment of psoriasis: a systematic review. Acta Derm Venereol. 2012;92(4):341-346.
6. Van Cranenburgh OD, De Korte J, Sprangers MAG, de Rie MA, Smets EM. Satisfaction with treatment among patients with psoriasis: a web-based survey study. Br J Dermatol. 2013;169(2):398-405.
7. van den Reek JM, van Luumig PP, Otero ME, et al. Satisfaction of treatment with biologics is high in psoriasis: results from the biocapture network. Br J Dermatol. 2014;170(5):1158-1165.
8. SchraaSchmidt ML, Kromer C, Herr R, Schmieder A, Goerdt S, Peitsch WK. Treatment satisfaction of patients with psoriasis. Acta Derm Venereol. 2015;95(5):572-578.
9. Ighani A, Yu AM, Sandhu VK, Barankin B, Manolson MF. Satisfaction and awareness of systemic psoriasis treatments: a national survey comparing biologic and nonbiologic users. J Cutan Med Surg. 2019;23(2):148-156.
10. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based multi-national assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol. 2014;70(5):871-881.
11. Barbosa CD, Balp MM, Kulich K, Germain N, Roifal D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39-48.
12. Renzi C, Tabolli S, Picardi A, Abeni D, Puddu P, Braga M. Effects of patient satisfaction with care on health-related quality of life: a prospective study. J Eur Acad Dermatol Venereol. 2005;19:712-718.
13. Kommehl H, Callis Duffin K, Salame N, et al. Examination of treatment satisfaction instruments in psoriasis: 2017 results from the psoriasis working Group of the International Dermatology Outcome Measures (IDEOM). Dermatology. 2021;237(2):151-157.
14. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.
15. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health. 2005;8(suppl 1):59-524.
16. Likert R. A technique for the measurement of attitudes. Arch Psychol. 1932;140:1-55.
17. http://www.quintiles.com/landing-pages/treatment-satisfactionquestionnaire-for-medication-tsqm
18. Gisondi P, Altmare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774-790.
19. Schäfer I, Hacker J, Rustenbach SJ, Radtke M, Franzke N, Augustin M. Concordance of the psoriasis area and severity index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol. 2010;20(1):62-67.
20. Vena GA, Cassano N, Esposito M, et al. Some considerations about the importance of alliance between patients and dermatologists in psoriasis. Clin Dermatol. 2014;23(3):147-151.
21. Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357-2367.
22. Linder D, Dall’olio E, Gisondi P, et al. Perception of disease and doctor-patient relationship experienced by patients with psoriasis: a questionnaire-based study. Am J Clin Dermatol. 2009;10(5):325-330.

**How to cite this article:** Esposito M, Giunta A, Gisondi P, et al. Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study. Dermatologic Therapy. 2021;34:e14949. https://doi.org/10.1111/dth.14949